Ironwood Pharmaceuticals, Inc. Board of Directors

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Mr. Thomas A. McCourt

Mr. Thomas A. McCourt

CEO, Principal Financial Officer & Director

Dr. Michael Shetzline M.D., Ph.D.

Dr. Michael Shetzline M.D., Ph.D.

Chief Medical Officer, Senior VP and Head of Research & Drug Development

Ms. Elizabeth Geary

Ms. Elizabeth Geary

Senior Vice President of Talent, Team & Culture

Mr. Greg Martini

Mr. Greg Martini

Vice President of Strategic Finance & Investor Relations

Mr. John Minardo

Mr. John Minardo

Senior VP, Chief Legal Officer & Secretary

Mr. Mike Nanfito

Mr. Mike Nanfito

Vice President of Sales & Sales Excellence

Dr. Rosario Lobrutto M.B.A., M.S., Ph.D.

Dr. Rosario Lobrutto M.B.A., M.S., Ph.D.

VP & Global Head of Technical Operations

Ms. Beth Calitri

Ms. Beth Calitri

VP of Corporate Communications & Media Relations

Mr. Ronald Silver

Mr. Ronald Silver

Corporate Controller & Principal Accounting Officer

Dr. Susanna Y. Huh M.D., M.P.H.

Dr. Susanna Y. Huh M.D., M.P.H.

VP & Head of Clinical Development

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.